Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery and Chemotherapy-Only for Wnt Positive Medulloblastoma
NCT02212574Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2017
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lomustine, vincristine sulfate liposome injection, Cisplatin micelle injection (HA132) and cyclophosphamide in medulloblastoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Progression Free Survival at 3 years. Started Apr 2017; status: terminated.
02
Drugs
lomustinevincristine sulfate liposome injectionCisplatin micelle injection (HA132)cyclophosphamide
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT02212574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212574.